Oncorus to Present at Upcoming Investor Conferences

Rhea-AI Summary

Oncorus, Inc. (Nasdaq: ONCR) announced participation in two virtual investor conferences. President and CEO Theodore Ashburn will present at the 33rd Annual Piper Sandler Virtual Healthcare Conference, with a replay available from November 22, 2021, and at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021. Oncorus focuses on next-generation viral immunotherapies aimed at improving cancer treatment outcomes, with key programs including ONCR-177, ONCR-021, and ONCR-788. Webcasts will be accessible on their website, archived for 30 days post-event.

CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming virtual investor conferences:

• 33^rd Annual Piper Sandler Virtual Healthcare Conference: A corporate presentation will be available on-demand starting Monday, November 22^nd at 10:00 a.m. ET.
• Evercore ISI 4th Annual HealthCONx Conference: Fireside chat on Wednesday, December 1^st, 2021 at 4:45 p.m. ET.

A webcast of each conference presentation will be available under the Investors & Media section of Oncorus’ website at https://investors.oncorus.com/. A replay of the presentations will be archived on Oncorus’ site for 30 days following the event.

About Oncorus
At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. We are advancing a portfolio of intratumorally (iTu) and intravenously (IV) administered viral immunotherapies for multiple indications with significant unmet need based on our oncolytic Herpes Simplex Virus (HSV) Platform and Synthetic viral RNA (vRNA) Immunotherapy Platform.

Designed to deliver next-generation viral immunotherapy impact, our HSV Platform improves upon key characteristics of this therapeutic class to enhance systemic activity. Our lead HSV program, ONCR-177, is designed to be directly administered into a tumor, resulting in high local concentrations of the therapeutic agent and its five encoded transgenes, as well as low systemic exposure to the therapy, which could limit systemic toxicities. Our pioneering Synthetic vRNA Immunotherapy Platform involves a highly innovative, novel combination of RNA- and oncolytic virus-based modalities designed to realize the potential of RNA medicines for cancer. Our lead IV-administered Synthetic vRNA Immunotherapy clinical candidates, ONCR-021 and ONCR-788, are both currently in IND-enabling studies.

Please visit www.oncorus.com to learn more.

Media Contact:                                
Liz Melone
liz@scientpr.com
                
Investor Contact:
Stern Investor Relations
Julie Seidel
Julie.seidel@sternir.com

FAQ

When is Oncorus participating in the Piper Sandler Virtual Healthcare Conference?

Oncorus will participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference, with a corporate presentation available on-demand starting November 22, 2021, at 10:00 a.m. ET.

What is the date and time of Oncorus's chat at the Evercore ISI HealthCONx Conference?

The fireside chat at the Evercore ISI 4th Annual HealthCONx Conference will take place on December 1, 2021, at 4:45 p.m. ET.

Where can I find the webcasts for Oncorus's investor conferences?

The webcasts of Oncorus's presentations will be available under the Investors & Media section of their website and archived for 30 days following each event.

What are the key programs mentioned by Oncorus in the press release?

The key programs highlighted by Oncorus include ONCR-177, ONCR-021, and ONCR-788, which are part of their viral immunotherapy portfolio.

What is the focus of Oncorus's viral immunotherapy platforms?

Oncorus focuses on next-generation viral immunotherapies, utilizing their oncolytic Herpes Simplex Virus and Synthetic viral RNA platforms to improve cancer treatment outcomes.